Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 1735  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
Table of Contents 
CME ARTICLE
Year : 2013  |  Volume : 58  |  Issue : 2  |  Page : 87-92
Update on cutaneous calciphylaxis


Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, 01067 Dresden, Germany

Date of Web Publication5-Mar-2013

Correspondence Address:
Uwe Wollina
Department of Dermatology and Allergology, Academic Teaching Hospital Dresden Friedrichstadt, Friedrichstrasse - 41, 01067 Dresden
Germany
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5154.108026

Rights and Permissions

   Abstract 

Calciphylaxis is a devastating disorder with a mortality rate of 80% due to sepsis and organ failure. Hallmarks of this rare disease are arteriolar media calcification, thrombotic cutaneous ischemia, and necrotic ulcerations. Different mechanisms of vascular calcification can lead to calciphylaxis. Early diagnosis by deep cutaneous ulcer biopsy is most important for prognosis. Here, dermatologists play a significant role although treatment usually needs an interdisciplinary approach. Surgical procedures had been the cornerstone of treatment in the past including parathyroidectomy, but recently new medical treatments emerged aiming to normalize disturbances of minerals to reduce the serum concentration of sodium phosphate and to prevent precipitation and calcification. Multimodal therapy is warranted but only aggressive surgical debridement of cutaneous ulcers has shown significant outcome improvement.


Keywords: Calciphylaxis, cutaneous ulcerations, medical treatment, surgery


How to cite this article:
Wollina U. Update on cutaneous calciphylaxis. Indian J Dermatol 2013;58:87-92

How to cite this URL:
Wollina U. Update on cutaneous calciphylaxis. Indian J Dermatol [serial online] 2013 [cited 2019 Jun 26];58:87-92. Available from: http://www.e-ijd.org/text.asp?2013/58/2/87/108026

What was known?
Calciphylaxis is an inflammatory disease of small and medium sized arteries characterized by calcification, thromboembolism, and painful cutaneous ulcerations. The most common underlying pathologies include end stage renal disease, diabetes mellitus, autoimmune disorders, and malignant disorders.



   Introduction Top


The term calciphylaxis had been coined by Selye in the early 1960s of the last century. He understood the disease as a kind of hypersensitivity and identified a number of "calcigens" (in analogy to allergens) involved in subcutaneous calcification. [1]

Nowadays, calciphylaxis is defined as a syndrome of progressive vascular media calcification due to various pathologies. Since the disease can be observed in patients with terminal renal insufficiency, the term calcific uremic arteriolopathy has been coined. [2] But renal pathology is not an essential for the development of calciphylaxis. [3]


   Definition Top


Calciphylaxis can be defined as a chronic progressive syndrome of arteriolar media calcification, thrombotic ischemia, and necrotic ulceration. Calciphylaxis develops when the levels of calcium and phosphate in the blood exceed their solubility range leading to deposits in the arteriolar walls. Systemic and cutaneous calciphylaxis are differentiated. Systemic calciphylaxis may lack ulcerations. [4]

In this review, we will exclusively focus on cutaneous calciphylaxis since this is the part of calciphylaxis the dermatologist may be confronted with. Severe ulcer pain is an important clinical symptom in cutaneous calciphylaxis. Cutaneous calciphylaxis can be subdivided into central and distal types. The distal type seems to have a better prognosis but evidence-based data are lacking. [5]


   Epidemiology Top


In a population-based study from Olmsted, MN, incidence was 4.5 per million inhabitants in a year. [6] The cumulative incidence of calciphylaxis among hemodialysis patients in the Western World is about 1% and prevalence is 4.1-4.4%. [4],[7],[8]


   Pathogenesis Top


The central mechanism in calciphylaxis is calcifying arteriolopathy, where vascular tissue develops into osteoid-like tissue. The smooth muscle cells of the vascular wall transdifferentiate into osteoid-like cells, a phenotypic shift that occurs without increase in proliferation. Several mechanisms may be involved: (a) A loss of inhibitors of calcification, (b) inducers of extra-osseous calcification, (c) circulating precipitating complexes, and (d) cell death. [9]

The initial step consists of inflammation with involvement of macrophages and vascular cells. [10],[11],[12] This is followed by paracrine signals mediated due to different signaling molecules such as bone morphogenetic protein-2 (BMP-2), Wnts, parathyroid hormone-related polypeptide, osteopontin, osteoprotegerin, and matrix Gla-protein. [13] A crucial factor in this pathway is phosphate. Phosphate is transported into the smooth muscle cells by type III sodium-dependent phosphate co-transporter Pit-1. BMP-2 stimulates phosphate uptake by smooth muscle cells. During this process, both Pit-1 messenger ribonuclei acid (mRNA) and Pit-1 protein are upregulated. [14]

In patients with terminal renal insufficiency, associated metabolic disturbances contribute to vascular calcification, such as hyperglycemia, hyperphosphatemia, hypercholesterolemia, hypertension, parathormone resistance, and iatrogenic calcitriol excess. [15]

Calcification of vascular walls increases stiffness, pulse wave velocity, and ischemic events, and increases cardiovascular morbidity and mortality. [16]

Associated disorders and risk factors

Terminal renal insufficiency is the most important disease associated with calciphylaxis. [2],[4],[5] There is a variety of identified risk factors in such patients for calciphylaxis development, including hyperphosphatemia; Ca phosphorous product, >70 mg 2 /dl 2 ; blood sedimentation rate, >30 mm/h; aluminum, >25ng/ml; increase in calcium levels; and decrease in serum albumin. [5],[17],[18] Concomitant medications such as calcium-based phosphate binders, vitamin K antagonists, and heparin are further risk factors. [5],[18],[19]

Another important group of associated diseases are autoimmune disorders, such as systemic lupus, rheumatoid arthritis, giant cell arteritis, and others. [20],[21],[22],[23]

In this group of disorders, renal involvement is not necessary for calciphylaxis. Precipitating factors could be systemic corticosteroid therapy and associated protein C or S deficiency. [5],[24]

Further associated disorders are hyperparathyroidism (adenoma or carcinoma; in case of secondary type, there is association with end-stage renal disease), diabetes mellitus, and hepatobiliary diseases. [5],[23],[24] Multiple myeloma, Hodgkin's disease, and lymphomatoid papulosis have been reported to be rarely associated with calciphylaxis. [25],[26]

Clinical presentation and diagnostics

Cutaneous calciphylaxis starts with non-characteristic cutaneous symptoms including subcutaneous nodules and infiltrated plaques. Purpuric- and livedo-like lesions may occur. Later stage is characterized by the development of progressive necrotic ulcers often with a bizarre shape and severe pain [Figure 1]a and b. Cutaneous ulceration is a strong negative prognostic factor. Ulcerations may be a starting point for septic complications associated with high mortality of 50-80%. [5],[23],[24] Distal cutaneous calciphylaxis is responsible for about 1.1% of leg ulcers seen in Germany. [27] Less common sites of cutaneous ulcerations are breasts and genitals. A deep skin biopsy (no punch biopsy) with subcutaneous adipose tissue is necessary to confirm diagnosis. The calcified arterioles are placed within the subcutaneous fat. A von Kossa stain is a reliable method to visualize calcified vascular walls for routine. The most common histopathological finding is a septal calcifying panniculitis. [5],[23]
Figure 1: Clinical presentation of distal cutaneous calciphylaxis. (a) A more recent ulceration with reddish wound ground and serous discharge. (b) A long-standing ulcer with fibrin coverage but no signs of re-epithelialization. (c) Situation after deep ulcer shaving with split-skin mesh-graft transplantation in the same setting

Click here to view


A net-like pattern of calcification has been described as characteristic for calciphylaxis in plain radiographs and may aid diagnosis. [28] Laboratory findings are non-specific and dependent on underlying pathologies.

Differential diagnoses

The initial stages of nephrogenic systemic fibrosis may resemble calciphylaxis, sometimes with extra-osseous calcification. [29] Calcinosis cutis is seen mainly with autoimmune collagen-vascular diseases, but ulceration is rare. Autoimmune vasculitis or panniculitis has to be considered. [17],[30],[31] Winiwarter-Buerger disease and ergotism can cause painful digital ulcerations. [31],[32] Calciphylaxis may clinically resemble pyoderma gangrenosum, but histopathology is different. [33]


   Treatment Top


In general, treatment of calciphylaxis is a multimodal and interdisciplinary approach. The major targets are interruption and/or reversal of vascular calcification and prevention of fatal septic complications.

Medical treatment

In case of end-stage renal disease, intensified hemodialysis and preference of products with a lower Ca content are essential. Primary goals of medical treatment are normalization of hyperparathyroidism, hypercalcemia, and hyperphosphatemia. None can reduce the risk of septic fatalities.

Non-calcium/non-aluminum - containing phosphate binders

Non-calcium/non-aluminum-containing phosphate binders like sevelamer hydrochloride or lanthanum carbonate should be preferred in calciphylaxis patients with end-stage renal disease. They may reduce arterial calcification in context with intensified hemodialysis. [34],[35]

Bisphosphonates

Amino-bisphosphonates inhibit soft tissue calcification. In animal models, bisphosphonates act on macrophages and bind to calcified vascular smooth muscle cells, thereby inhibiting progression of the process. Both oral etidronate disodium and intravenous pamidronate have been used successfully in individual calciphylaxis patients. [36],[37] The following dosages are used: Ibandronate, 150 mg monthly; alendronate, 70 mg weekly; or risedronate, 35 mg weekly.

Cinacalcet

Cinacalcet is a calcimimetic antagonist of parathormone which can normalize secondary hyperparathyroidism. The action is mediated by increasing sensitivity of Ca-sensing receptor on parathyroid glands. Doses are titrated from 30 to 180 mg/d. Wound pain is reduced in single cases but on long term, the drug can decrease bone mineral density. [38],[39]

Cinacalcet does not induce a long lasting of the autonomous growth of parathyroids. The effect is limited to the time of treatment.

Paricalcitol

Paricalcitol is a selective activator of vitamin D receptors. In animal models, aortic calcification was reduced. Anti-calcification factors such as osteopontin and klotho were upregulated. [40] There are case reports on positive effects on hemodialysis-associated calciphylaxis when used together with other drugs. [41],[42]

Sodium thiosulfate

Sodium thiosulfate is a chelating agent with anti-oxidant efficacy. The drug is used intravenously in calcifying nephrolithiasis and tumor-induced calcinosis. [43] In a literature review, 41 calciphylaxis patients treated in > 90% successfully have been identified. [44] In hemodialysis patients, improvement in cutaneous ulcers and pain was observed in about 70%. It is given intravenously in 25% in dextrose solution with a dosage of 25 g/1.73 m 2 after hemodialysis. Nevertheless, sodium thiosulfate was unable to reduce high mortality rate of 71%. [45]

Farnesoid X receptor agonists

Nuclear Farnesoid X receptor (FXR) is involved in regulation of lipid, carbohydrate, and bile acid metabolism. In cell culture and animal studies, FXR agonist, 6α-ethyl-chenodeoxycholic acid inhibits phosphate-induced mineralization of cells and ameliorate renal vascular calcification. [46] In the future, FXR agonist may represent a new class of drugs for medical treatment of calciphylaxis.

Pain control

Pain control is a significant part in the attempts to improve patient's quality of life. [47] A multimodal preventive analgesia with sufficient dosages of opioids, ketamine, or benzodiazepines is recommended. [48] In case of opioid-resistant pain, levomethadone has been used successfully. [49]

Wound debridement and surgery

Parathyroidectomy


The classical surgical attempt to calciphylaxis is hyperparathyroidism. Parathyroidectomy is curative in primary hyperparathyroidism. On the other hand, the procedure alone is not effective in secondary or tertiary hyperparathyroidism to improve outcome of calciphylaxis patients. [50] Patients after bariatric surgery need particular care since life-threatening hypocalcemia has been observed after parathyroidectomy. [51]

Surgery of cutaneous ulcers

Whether or not aggressive wound debridement should be performed in calciphylaxis, has been a matter of debate. Those who argue against debridement fear an aggravation of cutaneous ulceration or believe that medical drug therapy is capable to prevent catastrophic outcome. [52],[53]

Wound debridement with sterile maggots has been used in individual cases successfully, but it is not always sufficient to induce complete ulcer healing. [54] Considering histopathology, debridement should aim not only to remove eschar and bacterial biofilms but also inflamed adipose tissue. The only legitimation for aggressive debridement is improvement of outcome by reduction of wound infection, sepsis, and organ failure.

Available data support this idea: Aggressive debridement improves the outcome of calciphylaxis patients. Debridement and parathyroidectomy resulted in a better outcome than parathyroidectomy alone. [41]

In a retrospective trial, patients who underwent surgical debridement showed a significant better 1-year survival rate compared to controls: 61.6% versus 27.6% (P0 = 0.008). [5]

Aggressive surgical debridement can be combined with split-skin mesh-graft transplantation [Figure 1]c. In a retrospective 3-year analysis of our patients with calciphylaxis, terminal renal insufficiency, and diabetes mellitus, the individual skin graft take rate was 30-90%. A complete wound closure was achieved in six of seven patients. We observed no surgery-related complications, no wound infection or sepsis. Patients reported about rapid improvement of quality of life and decreased pain. [55]

Negative pressure wound therapy can increase the take rate of skin grafts in chronic leg ulcers. [56] Whether its use in calciphylaxis offers an additional benefit for the patients can yet not be decided because of small numbers of published cases. [57]

Revascularization by vascular surgery, repeated aggressive debridement, and skin transplantation can improve the limb salvage rate. [58]

Hyperbaric oxygen therapy

Improved to wound healing of calciphylaxis patients was reported when hyperbaric oxygen therapy (HOT) was delivered as an adjuvant treatment in multiple sessions. [59],[60] The number of patients treated with HOT is small and the treatment has never been investigated as either single option or in a comparative trial.


   Conclusions Top


There is no doubt that calciphylaxis patients need interdisciplinary care. Multimodal therapy for renal end-stage-related calciphylaxis includes intensified hemodialysis with non-calcium/non-aluminum phosphate binders, sodium thiosulfate, cinacalcet, HOT, and parathyroidectomy without aggressive wound debridement resulted in failure of wound healing in 50% of patients with a mortality rate of 83%. [61]

There is still no consensus on the optimum treatment of calciphylaxis, but treatment should aim to close all cutaneous ulcers. Aggressive debridement and skin grafting may reduce the time until complete wound closure. Without aggressive debridement, the multimodal approach remains incomplete and the risk of sepsis remains high despite systemic antibiotic therapy.

CME-Questions

  1. Calciphylaxis is a potentially life-threatening disorder. What are the known risk factors?
    1. Obesity.
    2. End-stage renal disease.
    3. Psoriasis.
    4. Hodgkin's lymphoma.
  2. Calciphylaxis is often associated with underlying pathologies. Which one right?
    1. Helicobacter pylori causing gastritis.
    2. Hepatitis C infection.
    3. Systemic lupus erythematosus.
    4. Leprosy.
  3. Calciphylaxis diagnosis is based on which parameters?
    1. Histopathology of deep ulcer biopsies.
    2. Rapid growing painful skin ulcers.
    3. Increased blood glucose level.
    4. Increased serum iron level.
  4. What seems to be the best imaging technique for diagnosis of calciphylaxis?
    1. Thoracic X-ray.
    2. Mammography.
    3. Computerized tomography.
    4. Diagnostic ultrasound.
  5. Which stain is preferred to visualize vascular calcification?
    1. Hematoxylin-eosin.
    2. Alcian blue.
    3. Congo red.
    4. Von Kossa.
  6. When is parathyroidectomy curative in calciphylaxis?
    1. In any case of calciphylaxis.
    2. In renal end-stage related calciphylaxis.
    3. In primary hyperparathyroidism.
    4. Never.
  7. Which medical drugs have been identified as possible inducers or aggravators of calciphylaxis?
    1. Calcium-containing phosphate binders.
    2. Vitamin-K antagonists.
    3. Systemic corticosteroids.
    4. Levamisole.
  8. Which medical drugs seem to be beneficial in multimodal therapy of calciphylaxis?
    1. Heparin.
    2. Cinacalcet.
    3. Systemic corticosteroids.
    4. Sodium thiosulfate.
  9. What are the major causes of mortality in calciphylaxis?
    1. Cardiovascular events.
    2. Skin cancer.
    3. Massive bleeding.
    4. Sepsis.
  10. Which treatment has been shown to reduce the mortality risk?
    1. Cinacalcet.
    2. Sodium thiosulfate.
    3. Intensified hemodialysis.
    4. Aggressive surgical wound debridement.


 
   References Top

1.Selye H, Somogyi A, Mécs I. Calcergy inhibited by calciphylactic challengers. Science 1968;159:1361-2.  Back to cited text no. 1
    
2.Hafner J, Keusch G, Wahl C, Sauter B, Hürlimann A, von Weizsäcker F, et al. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): A complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 1995;33:954-62.  Back to cited text no. 2
    
3.Kalajian AH, Malhotra PS, Callen JP, Parker LP. Calciphylaxis with normal renal and parathyroid function: Not as rare as previously believed. Arch Dermatol 2009;145:451-8.  Back to cited text no. 3
    
4.Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. Kidney Int 2002;61:2210-7.  Back to cited text no. 4
[PUBMED]    
5.Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: Natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007;56:569-79.  Back to cited text no. 5
[PUBMED]    
6.Reed KB, Davis MD. The incidence of physician-diagnosed calciphylaxis: A population-based study. J Am Acad Dermatol 2007;57:365-6.  Back to cited text no. 6
[PUBMED]    
7.Esteve V, Almirall J, Luelmo J, Sáez A, Andreu X, García M. Calcific uraemic arteriolopathy (calciphylaxis): Incidence, clinical features and long term outcomes. Nefrologia 2007;27:599-604.  Back to cited text no. 7
    
8.Rogers NM, Coates PT. Calcific uraemic arteriolopathy: An update. Curr Opin Nephrol Hypertens 2008;17:629-34.  Back to cited text no. 8
[PUBMED]    
9.Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004;15:2959-64.  Back to cited text no. 9
[PUBMED]    
10.Lee JL, Naguwa SM, Cheema G, Gershwin ME. Recognizing calcific uremic arteriolopathy in autoimmune disease: An emerging mimicker of vasculitis. Autoimmun Rev 2008;7:638-43.  Back to cited text no. 10
[PUBMED]    
11.Rusanescu G, Weissleder R, Aikawa E. Notch signaling in cardiovascular disease and calcification. Curr Cardiol Rev 2008;4:148-56.  Back to cited text no. 11
[PUBMED]    
12.Simionescu A, Simionescu DT, Vyavahare NR. Osteogenic responses in fibroblasts activated by elastin degradation products and transforming growth factor-beta1: Role of myofibroblasts in vascular calcification. Am J Pathol 2007;171:116-23.  Back to cited text no. 12
[PUBMED]    
13.Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: An early perspective. Am J Physiol Endocrinol Metab 2004;286:E686-96.  Back to cited text no. 13
[PUBMED]    
14.Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008;199:271-7.  Back to cited text no. 14
[PUBMED]    
15.Yonova D. Vascular calcification and metabolic acidosis in end stage renal disease. Hippokratia 2009;13:139-40.  Back to cited text no. 15
[PUBMED]    
16.Karwowski W, Naumnik B, Szczepañski M, My?liwiec M. The mechanism of vascular calcification-a systematic review. Med Sci Monit 2012;18:RA1-11.  Back to cited text no. 16
    
17.Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001;60:324-32.  Back to cited text no. 17
[PUBMED]    
18.Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 2012;27:1580-4.  Back to cited text no. 18
    
19.Boccara O, Prost-Squarcioni C, Battistella M, Brousse N, Rongioletti F, Fraitag S. Calcinosis cutis: A rare reaction to subcutaneous injections of calcium-containing heparin in patients with renal failure. Am J Dermatopathol 2010;32:52-5.  Back to cited text no. 19
[PUBMED]    
20.Aliaga LG, Barreira JC. Calciphylaxis in a patient with systemic lupus erythematosus without renal insufficiency or hyperparathyroidism. Lupus 2012;21:329-31.  Back to cited text no. 20
[PUBMED]    
21.Malabu UH, Roberts LJ, Sangla KS. Calciphylaxis in a morbidly obese woman with rheumatoid arthritis presenting with severe weight loss and vitamin D deficiency. Endocr Pract 2011;17:e104-8.  Back to cited text no. 21
[PUBMED]    
22.Brouns K, Verbeken E, Degreef H, Bobbaers H, Blockmans D. Fatal calciphylaxis in two patients with giant cell arteritis. Clin Rheumatol 2007;26:836-40.  Back to cited text no. 22
[PUBMED]    
23.Wollina U. Cutaneous calciphylaxis. Hautarzt 2010;61:1063-71.  Back to cited text no. 23
[PUBMED]    
24.Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: A systematic review. Clin J Am Soc Nephrol 2008;3:1139-43.  Back to cited text no. 24
[PUBMED]    
25.Sibai H, Ishak RS, Halawi R, Otrock ZK, Salman S, Abu-Alfa A, et al. Non-uremic calcific arteriolopathy (calciphylaxis) in relapsed/refractory Hodgkin's lymphoma: A previously unreported association. J Clin Oncol 2012;30:e88-90.  Back to cited text no. 25
[PUBMED]    
26.Sullivan E, Hoyle C. Calciphylaxis, occurring 10 weeks after hypercalcaemia, in a patient with multiple myeloma. Br J Haematol 2011;155:136.  Back to cited text no. 26
[PUBMED]    
27.Körber A, Klode J, Al-Benna S, Wax C, Schadendorf D, Steinstraesser L, et al. Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey. J Dtsch Dermatol Ges 2011;9:116-21.  Back to cited text no. 27
    
28.Shmidt E, Murthy NS, Knudsen JM, Weenig RH, Jacobs MA, Starnes AM, et al. Net-like pattern of calcification on plain soft-tissue radiographs in patients with calciphylaxis. J Am Acad Dermatol 2012;67:1296-1301.e2.  Back to cited text no. 28
    
29.Song J, Volkov S, Shea CR, Alegre ML, Salgia R, Gregg K, et al. Nephrogenic systemic fibrosis associated with stromal and vascular calcification, report of two cases. J Cutan Pathol 2009;36:31-4.  Back to cited text no. 29
    
30.Lee JL, Naguwa SM, Cheema G, Gershwin ME. Recognizing calcific uremic arteriolopathy in autoimmune disease: An emerging mimicker of vasculitis. Autoimmun Rev 2008;7:638-43.  Back to cited text no. 30
    
31.Wollina U, Unger L, Haroske G, Heinig B. Classification of vascular disorders in the skin and selected data on new evaluation and treatment. Dermatol Ther 2012;25:287-96.  Back to cited text no. 31
    
32.Wollina U, Hansel G, Gruner M, Schönlebe J, Heinig B, Köstler E. Painful ANA-positive scleroderma-like disease with acral ulcerations: A case of chronic gangrenous ergotism. Int J Low Extrem Wounds 2007;6:148-52.  Back to cited text no. 32
    
33.Wollina U, Haroske G. Pyoderma gangraenosum. Curr Opin Rheumatol 2011;23:50-6.  Back to cited text no. 33
    
34.Baldwin C, Farah M, Leung M, Taylor P, Werb R, Kiaii M, et al. Multi-intervention management of calciphylaxis: A report of 7 cases. Am J Kidney Dis 2011;58:988-91.  Back to cited text no. 34
    
35.Nagano N, Miyata S, Obana S, Eto N, Fukushima N, Burke SK, et al. Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder. Nephron 2001;89:321-8.  Back to cited text no. 35
    
36.Shiraishi N, Kitamura K, Miyoshi T, Adachi M, Kohda Y, Nonoguchi H, et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006;48:151-4.  Back to cited text no. 36
    
37.Hanafusa T, Yamaguchi Y, Tani M, Umegaki N, Nishimura Y, Katayama I. Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. J Am Acad Dermatol 2007;57:1021-5.  Back to cited text no. 37
    
38.Mohammed IA, Sekar V, Bubtana AJ, Mitra S, Hutchison AJ. Proximal calciphylaxis treated with calcimimetic 'Cinacalcet'. Nephrol Dial Transplant 2008;23:387-9.  Back to cited text no. 38
    
39.Mitsopoulos E, Ginikopoulou E, Economidou D, Zanos S, Pateinakis P, Minasidis E, et al. Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: A pilot study. Am J Nephrol 2012;36:238-44.  Back to cited text no. 39
    
40.Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro OM, Moe OW, et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012;82:1261-70.  Back to cited text no. 40
    
41.Vargemezis V, Liakopoulos V, Kriki P, Panagoutsos S, Leontsini M, Passadakis P, et al. Pivotal role of paricalcitol in the treatment of calcific uremic arteriolopathy in the presence of a parathyroid adenoma. Am J Kidney Dis 2010;55:144-7.  Back to cited text no. 41
    
42.Kakagia D, Kriki P, Thodis E, Roumeliotis A, Vargemezis V. Calcific uremic arteriolopathy treated with cinacalcet, paricalcitol, and autologous growth factors. J Cutan Med Surg 2011;15:121-4.  Back to cited text no. 42
    
43.Hayden MR, Goldsmith D, Sowers JR, Khanna R. Calciphylaxis: Calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol 2008;40:443-51.  Back to cited text no. 43
    
44.Auriemma M, Carbone A, Di Liberato L, Cupaiolo A, Caponio C, De Simone C, et al. Treatment of cutaneous calciphylaxis with sodium thiosulfate: Two case reports and a review of the literature. Am J Clin Dermatol 2011;12:339-46.  Back to cited text no. 44
    
45.Noureddine L, Landis M, Patel N, Moe SM. Efficacy of sodium thiosulfate for the treatment for calciphylaxis. Clin Nephrol 2011;75:485-90.  Back to cited text no. 45
    
46.Miyazaki-Anzai S, Levi M, Kratzer A, Ting TC, Lewis LB, Miyazaki M. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease. Circ Res 2010;106:1807-17.  Back to cited text no. 46
    
47.Price P, Fogh K, Glynn C, Krasner DL, Osterbrink J, Sibbald RG. Managing painful chronic wounds: The Wound Pain Management Model. Int Wound J 2007;4:4-15.  Back to cited text no. 47
    
48.Polizzotto MN, Bryan T, Ashby MA, Martin P. Symptomatic management of calciphylaxis: A case series and review of the literature. J Pain Symptom Manage 2006;32:186-90.  Back to cited text no. 48
    
49.Poels M, Joppich R, Gerbershagen K, Wappler F. [Analgesic therapy of calciphylaxis with levomethadone: A case study]. Schmerz 2010;24:621-4.  Back to cited text no. 49
    
50.Lal G, Nowell AG, Liao J, Sugg SL, Weigel RJ, Howe JR. Determinants of survival in patients with calciphylaxis: A multivariate analysis. Surgery 2009;146:1028-34.  Back to cited text no. 50
    
51.Palal B, Sinsakul M, Reutrakul S. Life-threatening hypocalcemia following subtotal parathyroidectomy in a patient with renal failure and previous roux-en-Y gastric bypass surgery. Case Report Endocrinol 2011;2011:370583.  Back to cited text no. 51
    
52.Bechara FG, Altmeyer P, Kreuter A. Should we perform surgical debridement in calciphylaxis? Dermatol Surg 2009;35:554-5.  Back to cited text no. 52
    
53.Meissner M, Gille J, Kaufmann R. Calciphylaxis: No therapeutic concepts for a poorly understood syndrome? J Dtsch Dermatol Ges 2006;4:1037-44.  Back to cited text no. 53
    
54.Tittelbach J, Graefe T, Wollina U. Painful ulcers in calciphylaxis-combined treatment with maggot therapy and oral pentoxyfillin. J Dermatolog Treat 2001;12:211-4.  Back to cited text no. 54
    
55.Wollina U, Helm C, Hansel G, Koch A, Schönlebe J, Haroske G, et al. Deep ulcer shaving combined with split-skin transplantation in distal calciphylaxis. Int J Low Extrem Wounds 2008;7:102-7.  Back to cited text no. 55
    
56.Körber A, Franckson T, Grabbe S, Dissemond J. Vacuum assisted closure device improves the take of mesh grafts in chronic leg ulcer patients. Dermatology 2008;216:250-6.  Back to cited text no. 56
    
57.Emohare O, Kowal-Vern A, Wiley D, Latenser BA. Vacuum-assisted closure use in calciphylaxis. J Burn Care Rehabil 2004;25:161-4.  Back to cited text no. 57
    
58.Milas M, Bush RL, Lin P, Brown K, Mackay G, Lumsden A, et al. Calciphylaxis and nonhealing wounds: The role of the vascular surgeon in a multidisciplinary treatment. J Vasc Surg 2003;37:501-7.  Back to cited text no. 58
    
59.Arenas MD, Gil MT, Gutiérrez MD, Malek T, Moledous A, Salinas A, et al. Management of calcific uremic arteriolopathy (calciphylaxis) with a combination of treatments, including hyperbaric oxygen therapy. Clin Nephrol 2008;70:261-4.  Back to cited text no. 59
    
60.Banerjee C, Woller SC, Holm JR, Stevens SM, Lahey MJ. Atypical calciphylaxis in a patient receiving warfarin then resolving with cessation of warfarin and application of hyperbaric oxygen therapy. Clin Appl Thromb Hemost 2010;16:345-50.  Back to cited text no. 60
    
61.Malabu UH, Manickam V, Kan G, Doherty SL, Sangla KS. Calcific uremic arteriolopathy on multimodal combination therapy: Still unmet goal. Int J Nephrol 2012;2012:390768.  Back to cited text no. 61
    

What is new?
The major clue to understanding of calciphylaxis is the discovery of vascular smooth muscle cell transdifferentiation. No targeted therapy has been developed, yet FXR receptor antagonists are on the horizon. Multimodal therapy is incomplete without aggressive surgical debridement.


    Figures

  [Figure 1]

This article has been cited by
1 Calciphylaxis: from the disease to the diseased
Tiago M. Oliveira,Joćo M. Frazćo
Journal of Nephrology. 2015;
[Pubmed] | [DOI]
2 Falsely increased chloride and missed anion gap elevation during treatment with sodium thiosulfate
Wendroth, S.M., Heady, T.N., Haverstick, D.M., (...), Boyd, J.C., Bruns, D.E.
Clinica Chimica Acta. 2014;
[Pubmed]
3 Falsely increased chloride and missed anion gap elevation during treatment with sodium thiosulfate
Scott M. Wendroth,Tiffany N. Heady,Doris M. Haverstick,Lorin M. Bachmann,Mitchell G. Scott,James C. Boyd,David E. Bruns
Clinica Chimica Acta. 2014; 431: 77
[Pubmed] | [DOI]
4 Ulcus cruris
U. Wollina,L. Unger,C. Stelzner,J. Machetanz,S. Schellong
Der Internist. 2013;
[Pubmed] | [DOI]
5 Ulcus cruris | [Leg ulcers]
Authors of Document Wollina, U., Unger, L., Stelzner, C., Machetanz, J., Schellong, S.
Source of the Document Internist. 2013;
[Pubmed]



 

Top
Print this article  Email this article
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (635 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Definition
   Epidemiology
   Pathogenesis
   Treatment
   Conclusions
    References
    Article Figures

 Article Access Statistics
    Viewed4421    
    Printed88    
    Emailed0    
    PDF Downloaded277    
    Comments [Add]    
    Cited by others 5    

Recommend this journal